Use: Labeled indications
- to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis.
- to alkalinize the urine in drug poisoning in adult and pediatric patients in cases in which urinary drug elimination is enhanced by urinary alkalinaztion.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Sodium bicarbonate injection is an alkalinizing agent indicated:
- to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis. (1.1)
- to alkalinize the urine in drug poisoning in adult and pediatric patients in cases in which urinary drug elimination is enhanced by urinary alkalinaztion. (1.2) Limitation of Use Do not use sodium bicarbonate injection in settings where rapid administration of sodium bicarbonate is required, such as cardiac arrest. In such situations use a more concentrated solution. 1.1 Treatment of Clinically Significant Metabolic Acidosis Sodium bicarbonate injection is indicated to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis. 1.2 Urinary Alkalization in Drug Poisoning Sodium bicarbonate injection is indicated to alkalinize the urine in drug poisoning in adult and pediatric patients in cases in which urinary drug elimination is enhanced by urinary alkalinaztion. Limitation of Use Do not use sodium bicarbonate injection in settings where rapid administration of sodium bicarbonate is required, such as cardiac arrest. In such situations use a more concentrated solution.
Contraindications
- Chloride loss from vomiting or continuous gastrointestinal suction
- Diuretics that cause hypochloremic alkalosis
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (4)
Dosing: Adult
- Metabolic acidosis (IV, adults): 2 to 5 mEq/kg over 4 to 8 hours, guided by blood gases and clinical state
- CKD metabolic acidosis (oral tablets; KDIGO 2024): Consider treatment to keep serum bicarbonate from falling below 18 mmol/L, without exceeding the upper limit of normal; 650 mg tablet ≈ 7.7 mEq, 325 mg ≈ 3.9 mEq. No oral dose in the US label.
- Sodium bicarbonate injection is administered by intravenous infusion. (2.1)
- Do NOT dilute prior to administration. (2.1)
- Recommended Dosage in Adults and Pediatric Patients 2 Years of Age and Older Administer 2 mEq/kg to 5 mEq/kg of sodium bicarbonate injection over a four-to eight-hour period, depending upon the severity of metabolic acidosis as assessed by serum bicarbonate concentration, total CO 2, blood pH and the clinical condition of the patient. (2.2)
- Recommended Dosage in Pediatric Patients Less Than 2 Years of Age, including Neonates Administer 1 mEq/kg to 2 mEq/kg of sodium bicarbonate injection over a four-to eight-hour period. Avoid rapid or bolus administration. (2.2)
2.1 General Administration Instructions
2.1 General Administration Instructions Inspect parenteral drug products for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy or if it contains particulate matter. Discard any unused portion. Sodium bicarbonate injection is a ready to administer product that requires no further dilution prior to infusion.
Administer sodium bicarbonate injection by intravenous infusion, via a dedicated line. Individualize dosage depending on the severity of the acidosis. Treatment of metabolic acidosis with sodium bicarbonate should be superimposed on measures designed to address the underlying cause of metabolic acidosis.
2.2 Recommended Dosage
2.2 Recommended Dosage Recommended Dosage in Adults and Pediatric Patients 2 Years of Age and Older Administer 2 mEq/kg to 5 mEq/kg of sodium bicarbonate injection over a four- to eight-hour period, depending upon the severity of metabolic acidosis as assessed by serum bicarbonate concentration, total CO 2, blood pH and the clinical condition of the patient. Recommended Dosage in Pediatric Patients Less Than 2 Years of Age, including Neonates Administer 1 mEq/kg to 2 mEq/kg of sodium bicarbonate injection over a four- to eight-hour period.
Avoid rapid or bolus administration [see Warnings and Precautions (5.2), Use in Specific Populations (8.4)].
Dosing: Altered kidney function
Sodium bicarbonate is an alkalinizing agent; the bicarbonate is handled by the kidney and lungs, so there is no kidney dose reduction. The kidney concern is the sodium load: the US label (isotonic IV solution) asks for monitoring for fluid overload in kidney disease and anuria, plus electrolytes to avoid alkalosis and hypernatremia. Oral tablets used for the metabolic acidosis of CKD are outside this label; KDIGO 2024 suggests considering treatment when serum bicarbonate is below 18 mmol/L, without overshooting the upper limit of normal.
Kidney function measure: Not applicable: dosing is by acid-base status, not kidney function.
Show full dosing details
- CrCl ≥60 mL/min
- IV for metabolic acidosis (adults and children 2 years and older): 2 to 5 mEq/kg over 4 to 8 hours, by bicarbonate, total CO2, pH and clinical state (label). Treat the cause.
- CrCl 30–59 mL/min
- No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
- CrCl 15–29 mL/min
- No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
- CrCl <15 mL/min (not on dialysis)
- No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
- Hemodialysis (intermittent)
- No dose change; anuria raises the risk of fluid overload from the sodium load (label 5.1). Dialysate bicarbonate also corrects acidosis; coordinate with the dialysis prescription (clinical judgment).
- Peritoneal dialysis
- No dose change; watch sodium load and fluid status (label 5.1).
- CRRT
- No data in label. CRRT fluids are usually bicarbonate-buffered; added IV bicarbonate is a specialist decision guided by blood gases.
- Dialyzable? Bicarbonate crosses dialysis membranes in both directions according to the dialysate bicarbonate concentration (physiology; not stated in label).
- Monitoring Blood gases or serum bicarbonate, sodium, potassium (hypokalemia as acidosis corrects), fluid status, blood pressure, edema. Extravasation site (hypertonic solutions).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Dose by acid-base status (label).
- eGFR 30–59
- No dose change; watch sodium load and fluid status (label 5.1).
- eGFR 15–29
- No dose change; watch sodium load.
- eGFR <15 (not on dialysis)
- No dose change; watch sodium load.
- Hemodialysis (intermittent)
- No dose change; fluid overload risk (label 5.1).
- Peritoneal dialysis
- No dose change; watch sodium load.
- CRRT
- No data; specialist.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Dosing: Pediatric
- Approved ages
- All ages, including neonates (label).
- Usual dose
- 2 years and older: 2 to 5 mEq/kg over 4 to 8 hours. Under 2 years and neonates: 1 to 2 mEq/kg over 4 to 8 hours; avoid rapid or bolus doses (label).
- Maximum dose
- Under 2 years: rate no more than 8 mEq/kg/day (label 8.4).
- Neonates
- 1 to 2 mEq/kg over 4 to 8 hours; no more than 8 mEq/kg/day; rapid injection risks hypernatremia and intracranial hemorrhage (label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use Sodium bicarbonate injection is indicated in pediatric patients:
- To raise plasma pH in pediatric patients with clinically significant metabolic acidosis
- To alkalinize the urine in drug poisoning in cases in which urinary drug elimination is enhanced by urinary alkalinization Rapid injection of sodium bicarbonate injection solutions into neonates and children under two years of age may produce hypernatremia, a decrease in cerebrospinal fluid pressure and possible intracranial hemorrhage. The rate of administration in such patients should therefore be limited to no more than 8 mEq/kg/day.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of sodium bicarbonate injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
Administration
2.1 General Administration Instructions Inspect parenteral drug products for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy or if it contains particulate matter. Discard any unused portion. Sodium bicarbonate injection is a ready to administer product that requires no further dilution prior to infusion. Administer sodium bicarbonate injection by intravenous infusion, via a dedicated line. Individualize dosage depending on the severity of the acidosis. Treatment of metabolic acidosis with sodium bicarbonate should be superimposed on measures designed to address the underlying cause of metabolic acidosis.
US FDA labelDosage forms
Philippines
- Solution for injection: 50 mg/mL, 84 mg/mL
- Tablet: 325 mg, 650 mg
- Solution for iv injection: 84 mg/mL
- Solution: 3 g/100 mL, 208.75 mg/5 mL
- ) solution for infusion: 1 mEq/mL
- ) solution for injection: 84 mg/mL
- Film-coated tablet: 650 mg
- Solution for intravenous infusion: 84 mg/mL
- Solution for intravenous injection: 84 mg/mL
Registered products in the Philippines
68 products registered with the Food and Drug Administration (FDA) Philippines list Sodium bicarbonate as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Sodium Bicorbonate (1 product). Products registered under these spellings are included in the table and marked.
All registered products68
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AccenateSodium Bicarbonate | 650 mg TabletAmber Glass Bottle x 100's (Box of 1's) | OTC | Opal Laboratories (Pvt.) Limited.Pakistan | Accesspoint International Trading Inc. | DRP-17457 | Dec 19, 2030 | |
AcidNormSodium bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50’s) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Marcburg Philippines, Inc.Importer: JLT Pharma, Inc. | DRP-10801-02 | Dec 21, 2031 | |
AenabiSodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I colorless glass ampoule in PVC plastic tray x 10 mL (Box of 50's) and 20 mL ( Box of 50's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Dynasty PharmaceuticalsImporter: PhilRx Pharma Inc. | DRP-12551-02 | Sep 9, 2027 | |
AlkarbSodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (IV)USP type I white ampoule x 10 mL (Box of 5's) | Rx | Unijules Life Sciences LimitedIndia | Aglobal Care, Inc. | DRP-15405 | Jul 2, 2029 | |
Balsamo CarminativoSodium Bicarbonate | 208.75 mg/5 mL SolutionClear Plastic bottle x 15 mL; Clear Plastic bottle x 30 mL; Clear Plastic bottle x 60 mL; Clear Plastic bottle x 120 mL | HR | Ace Pharmaceuticals, Inc.Philippines | — | HRP-350 | May 7, 2028 | |
Bicarbillen-PE84Sodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (IV Infusion)10 mL and 20 mL USP Type I clear glass ampoule (Box of 50’s) | Rx | Penam Biosciences Pvt. Ltd.India | Ollen Pharma Trading Inc. | DRP-18593 | Aug 4, 2031 | |
BicarbisaphSodium Bicarbonate | 650 mg TabletAmber Glass Bottle with ROPP Cap x 100's (Box of 100's) | OTC | Sapphire Lifesciences Pvt. Ltd.India | Ollen Pharma Trading Inc.Trader: Shree Sainath International | DRP-13895 | May 12, 2028 | |
BicarbisaphSodium bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 10 mL and 20 mL (net content) in PVC Plastic Tray (Box of 50's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences Inc. | DRP-11307 | Nov 23, 2026 | |
BicarbolenSodium Bicarbonate | 325 mg TabletAmber glass bottle x 100's with ROPP cap (Box of 1's) | OTC | Sapphire Lifesciences Pvt., Ltd.India | Ollen Pharma Trading Inc. | HRP-635 | Nov 24, 2028 | |
Bicarbollen-B84Sodium Bicarbonate | 84mg/mL (8.4 w/v) Solution For Injection (IV Infusion)Type I Clear Glass Ampoule x 10 mL and 20 mL (Box of 50's) | Rx | Belco PharmaIndia | Ollen Pharma Trading Inc. | DRP-18973 | Oct 8, 2031 | |
BicarbozenSodium Bicarbonate | 650 mg TabletHDPE Plastic Bottle x 30's, 60's, and 100's with HDPE Screw Cap | OTC | Azarias Pharmaceutical Laboratories, Inc.Philippines | Kodapharm Med Corp. | DRP-9492-04 | Jan 25, 2031 | |
BicardikonSodium Bicarbonate | 84 mg/mL (8.4% w/v)Solution for Injection (I.V.)USP Type I clear glass ampoule x 20 mL in plastic tray (Box of 10's) | Rx | Jeil Pharmaceutical Co., Ltd.Republic of Korea | Pharmakon Pharmaceutical Inc.Importer: H & B Pharma International Inc. | DRP-12382--03 | Jul 29, 2027 | |
BicardoneSodium bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Ellebasy Medicale TradingImporter: JLT Pharma Inc. | DRP-10801-06 | Dec 21, 2026 | |
BicargenSodium Bicarbonate | 325 mg TabletHDPE Plastic Bottle with HDPE Screw Cap x 30's, 60's and 100's | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-9212 | Nov 25, 2030 | |
BicargenSodium Bicarbonate | 650 mg TabletHDPE Plastic Bottle with HDPE Screw Cap x 60's N/A | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Trader: Eba Generisch Trading Inc. | DRP-9213 | Nov 25, 2030 | |
BicarlifeSodium Bicarbonate | 650 mg TabletAlu-Dark Maroon PVC (Box of 100's) | OTC | Innovative HealthcareIndia | Biophil Medical Equipment and Supplies Trading | DRP-17625 | Feb 10, 2031 | |
BicarnateSodium Bicarbonate | 325 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's) Alu/Clear PVC Blister Pack x 20's (Box of 100's) | OTC | Azarias Pharmaceutical Laboratories, Inc.Philippines | — | DRP-14829 | Jan 17, 2029 | |
BicarnateSodium Bicarbonate | 325 mg TabletHDPE Plastic Bottle x 30's, 60's and 100's with HDPE Screw Cap | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-9493 | Jan 25, 2031 | |
BicarnateSodium Bicarbonate | 650 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | OTC | Azarias Pharmaceutical Laboratories, Inc.Philippines | — | DRP-14828 | Jan 17, 2029 | |
BicarnateSodium Bicarbonate | 650 mg TabletHDPE Plastic Bottle x 30's, 60's, and 100's with HDPE Screw Cap | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-9492 | Jan 25, 2031 | |
BicarsaphSodium Bicarbonate | 325 mg TabletAlu/Dark Maroon PVC Blister Pack x 10’s (Box of 100’s) | HR | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | HR-P577 | Oct 19, 2031 | |
325 mg TabletAlu/Dark Maroon PVC Blister Pack x 10's (Box of 100's) | HR | Sapphire Lifesciences Pvt. Ltd.India | Nelpa Lifesciences, Inc. | HRP-577 | Mar 13, 2028 | ||
BisolunateSodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I clear glass ampoule x 20 mL in plastic tray (Box of 10's) | Rx | Jeil Pharmaceutical Co., Ltd.Republic of Korea | Novapharma Healthcare Inc.Importer: H & B Pharma International Inc. | DRP-12382-07 | Jul 29, 2027 | |
BykarSodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (IV)USP Type I clear glass ampoule x 20 mL in plastic tray (Box of 10's) | Rx | Jeil Pharmaceutical Co., Ltd.Republic of Korea | The Cathay Drug Co., Inc.Importer: H & B Pharma International Inc. | DRP-12382-06 | Jul 29, 2027 | |
GodariseSodium Bicarbonate | 84 mg/mL (8.4 % w/v) Solution for Injection ( I.V. Infusion )USP Type I Colorless Glass Ampoule x 10 ml and 20 ml (net content) in PVC Plastic Tray (Box of 50's) | Rx | Kilitch Drugs (India) Ltd.India | Go Healthcare Pharmaceutical DistributionImporter: Nelpa Lifesciences Inc. | DRP-11307-01 | Nov 23, 2026 | |
KarbonetSodium Bicarbonate | 325 mg TabletHDPE Plastic Bottle x 60's with HDPE Screw Cap | OTC | Azarias Pharmaceutical Laboratories, Inc.Philippines | Konzept Convenience and Drugstore Corp. | DRP-9493-02 | Jan 25, 2031 | |
KarbonetSodium Bicarbonate | 650 mg TabletHDPE Plastic Bottle x 60's with HDPE Screw Cap | OTC | Azarias Pharmaceutical Laboratories, Inc.Philippines | Konzept Convenience and Drugstore Corp. | DRP-9492-02 | Jan 25, 2031 | |
KonabiSodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I clear glass ampoule x 20 mL in plastic tray (Box of 10's) | Rx | Jeil Pharmaceutical Co., Ltd.Republic of Korea | Dynasty PharmaceuticalsImporter: H & B Pharma International Inc. | DRP-12382-04 | Jul 29, 2027 | |
KurbacidSodium bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50’s) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Kurtmed Medical Distribution Inc.Importer: JLT Pharma Inc. | DRP-10801-09 | Dec 21, 2031 | |
MaxnateSodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for IV InjectionType II Glass Vial x 50 mL (Box of 1's) | Rx | Maxitech Pharma (Pvt) LtdPakistan | Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc. | DRP-15650 | Aug 14, 2029 | |
NacozidSodium Bicarbonate | 650 mg Film-Coated TabletHDPE BOTTLE x 60’s (BOX of 1's) | OTC | UNI MEDICOLABSIndia | Greencore Pharma Inc. | DRP-18578 | Jul 30, 2031 | |
NahcoSodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for IV InjectionType II Glass Vial x 50 mL (Box of 1's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Euro-Care Products PhilippinesImporter: Accesspoint International Trading Inc. | DRP-15650-01 | Aug 14, 2029 | |
NapracidSodium Bicarbonate | 325mg TabletClear PVC Blister Pack x 10's (Box of 100's) | OTC | Drugmaker's Laboratories Inc.Philippines | — | DRP-12999 | Nov 16, 2027 | |
NapracidSodium Bicarbonate | 650 mg TabletClear PVC Blister Pack x 10's (Box of 100's) | OTC | Drugmaker's Laboratories Inc.Philippines | — | DRP-13000 | Nov 16, 2027 | |
NeutrazSodium Bicarbonate | 650 mg TabletHDPE Bottle x 100's (Box of 1's) | OTC | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17330 | Nov 18, 2030 | |
NoneSodium bicarbonate | 325 mg TabletAmber Glass Bottle x 100's | OTC | Amherst Laboratories, Inc.Philippines | Trader: Philusa Corporation | DR-XY26820 | Jun 26, 2028 | |
NoneSodium Bicarbonate | 325 mg TabletAmber Glass Bottle x 100's with Metal Screw Cap | OTC | Amherst Laboratories. Inc.Philippines | Trader: Ritemed Phils., Inc. | DRP-8073 | Jan 15, 2029 | |
NoneSodium Bicarbonate | 650 mg tabletAmber Glass Bottle x 100 tablets | OTC | AMHERST LABORATORIES, INC.Philippines | Trader: PHILUSA CORPORATION | DR-5070 | May 29, 2028 | |
NoneSodium Bicarbonate | 650 mg TabletAlu/Dark Maroon-Colored PVC Blister Pack x 10’s (Box of 100’s) | OTC | Sai Parenterals Ltd.India | Ollen Pharma Trading, Inc.Trader: N/A | DRP-13745 | Jul 21, 2031 | |
NoneSodium Bicarbonate | 650 mg TabletAmber Glass Bottle x 100's with Metal Screw Cap | OTC | Amherst Laboratories. Inc.Philippines | Trader: Ritemed Phils., Inc. | DRP-8074 | Jan 15, 2029 | |
NoneSodium Bicarbonate | 650 mg TabletHDPE Plastic Bottle x 60's with HDPE Screw Cap | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | Hale Medipoint Corp. | DRP-9492-03 | Feb 10, 2032 | |
NoneSodium Bicarbonate | 8.4 % (1 mEq/mL) Solution for Infusion (IV)Type I Clear Colorless Glass Ampoule x 10 mL and 50 mL (Box of 50's) | Rx | Atlantic Laboratories Corporation Ltd.Thailand | Phil Pharmawealth, Inc. | DR-XY28703 | Jun 12, 2028 | |
NoneSodium Bicarbonate | 8.4% Solution for IV InfusionClear Colorless USP Type I Glass Bottle sealed with EPDM Rubber Stopper | Rx | B. Braun Melsungen AGGermany | Importer: B. Braun Medical Supplies, Incorporated | DR-XY15571 | Apr 18, 2031 | |
NoneSodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I colorless glass ampoule in PVC plastic tray x 10 mL (Box of 50's); USP Type I colorless glass ampoule in PVC plastic tray x 20 mL (Box of 50's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc.Importer: PhilRx Pharma Inc. | DRP-12551-01 | Sep 9, 2027 | |
NoneSodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for IV InjectionType II Glass Vial x 50 mL (Box of 1's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Reta DrugImporter: Accesspoint International Trading Inc | DRP-15650-03 | Aug 14, 2029 | |
QodicSodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I clear glass ampoule x 20 mL in plastic tray (Box of 10's) | Rx | Jeil Pharmaceutical Co., Ltd.Republic of Korea | Amediqo Phils., Inc.Importer: H & B Pharma International Inc. | DRP-12382-02 | Jul 29, 2027 | |
RcarbonateSodium Bicarbonate | 650mg TabletHDPE Bottle x 60's with HDPE Screw Cap | OTC | Azarias Pharmaceutical Laboratories Inc.Philippines | Trader: St. Raphael, The Archangel Pharmaceutical Distributor | DRP-12527 | Aug 26, 2027 | |
RobicarbSodium bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50’s) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Rx Global Sales and Mktg. Corp.Importer: JLT Pharma Inc. | DRP-10801-08 | Dec 21, 2031 | |
Royalenate®Sodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Intravenous InfusionUSP Type I Clear and colorless glass vial with bromobutyl rubber stopper and aluminum crimp seal and gray plastic cap x 20 mL (Box of 10's) and 50 mL (Box of 6's) | Rx | Royale Life Pharma Inc.Philippines | — | DRP-13257 | Jan 19, 2028 | |
RoybicarbSodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I clear and colorless glass vial x 20 mL and ess glass vial x 20 mL and 50 mL (net content) with grey bromobutyl rubber stopper, aluminum seal, and yellow plastic cap (Box of 15's) | Rx | Royale Life Pharma Inc.Philippines | — | DRP-17010 | Sep 5, 2030 | |
Sobi-KSodium bicarbonate | 84 mg / mL (8.4 w/v) Solution for IV InjectionType II Glass Vial x 50 mL (Box of 1's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Kurtmed Medical Distribution Inc.Importer: Accesspoint International Trading Inc. | DRP-15650-02 | Aug 14, 2029 | |
SobicardSodium bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50's) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Ellebasy Medicale Group Inc.Importer: JLT Pharma, Inc. | DRP-10801-03 | Dec 21, 2026 | |
SobinateSodium bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50’s) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Greencore Pharma Inc.Importer: JLT Pharma Inc. | DRP-10801 | Dec 21, 2031 | |
SobirlifeSodium Bicarbonate | 325 mg TabletAlu-Dark Maroon PVC Blister Pack x 10's (Box of 100's) | OTC | Flourish PharmaIndia | Biophil Medical Equipment and Supplies Trading | DRP-16565 | Apr 29, 2030 | |
SobitrisSodium Bicarbonate | 50 mg/mL (5% w/v) Solution for Injection (IV)USP Type I Clear Glass Vial Ampoule x 1 mL and 2 mL (Box of 10's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-17343 | Nov 19, 2030 | |
SodicarbSodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I clear glass ampoule x 20 mL in plastic tray (Box of 10's) | Rx | Jeil Pharmaceutical Co., Ltd.Republic of Korea | RCT Med Pharma CorporationImporter: H & B Pharma International Inc. | DRP-12382-05 | Jul 29, 2027 | |
SodiqoSodium bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50’s) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Amediqo Phils., Inc.Importer: JLT Pharma, Inc. | DRP-10801-04 | Dec 21, 2031 | |
SodrogenSodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I colorless glass ampoule in PVC plastic tray x 10 mL (Box of 10's and 50's); USP Type I colorless glass ampoule in PVC plastic tray x 20 mL (Box of 10's and 50’s) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Vintel Med EnterprisesImporter: PhilRx Pharma Inc. | DRP-12551-03 | Sep 9, 2027 | |
SodulaneSodium bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content) (Box of 50’s) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Medlane Pharma Inc.Importer: JLT Pharma Inc. | DRP-10801-05 | Dec 21, 2031 | |
SolucentSodium bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V. Infusion)USP Type I Colorless Glass Ampoule x 20 mL (net content). Box of 50's | Rx | BC WORLD Pharm. Co., Ltd.Republic of Korea | Central West Medicale Inc.Importer: JLT Pharma, Inc. | DRP-10801-01 | Dec 21, 2026 | |
SolunateSodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (IV)USP Type I Clear Glass Ampoule x 20 mL (Box of 50's) | Rx | Dai Han Pharm. Co., Ltd.Korea | Endure Medical Inc. | DR-XY44425 | Apr 16, 2031 | |
UnbrandedSodium Bicarbonate (Balsamo Carminativo) | 3 g/100 mL (3% w/v) SolutionWhite Translucent HDPE Bottle 30 mL; White Translucent HDPE Bottle 60 mL; White Translucent HDPE Bottle 120 mL | Rx | Maridan Industries, Inc.Philippines | — | DRHR-1976 | Apr 6, 2031 | |
UnicarbSodium bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection(I.V. Infusion)USP Type I Colorless Glass Ampoule x 20mL(net content) (Box of 50's) | Rx | BC World Pharm. Co., Ltd.Republic of Korea | Zen Pharma IncorporationImporter: JLT Pharma Inc. | DRP-10801-07 | Dec 21, 2026 | |
United Home Supracid Extra StrengthSodium Bicarbonate | 650 mg TabletHDPE Bottle x 100's | HR | Unilab, Inc.Philippines | — | DRHR-539 | Mar 7, 2037 | |
(no brand name)Sodium Bicarbonate | 8.4% (84 mg/mL) Solution for Injection (IV)Clear Vial x 50 mL (Box of 1's) | Rx | Hospira, Inc.U.S.A. | Pfizer, Inc | DR-XY6202 | Jul 30, 2030 | |
(no brand name)Sodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V.)Abboject Syringe (Calibrated USP Type I Glass Vial with Blue Butyl Rubber and Plastic Syringe Barrel) (Box of 1's) | Rx | Hospira, Inc.U.S.A. | Pfizer, Inc | DR-XY17168 | Jul 16, 2030 | |
(no brand name)Sodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Injection (I.V.)USP Type I colorless glass ampoule in PVC plastic tray x 10 mL (Box of 50's) and 20 mL (Box of 50's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc. | DRP-12551 | Sep 9, 2027 | |
(no brand name)Sodium Bicarbonate | 84 mg/mL (8.4% w/v) Solution for Intravenous (IV) InjectionUSP Type I Clear Glass Ampoule x 10 mL (Box of 50's) | Rx | Aculife Healthcare Private LimitedIndia | Blue Global (FZE) | DRP-12825 | Oct 11, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Sodium Bicarbonate Injection is a clear, colorless, sterile, nonpyrogenic, isotonic solution intended for intravenous use and available as: Injection: 12.6 mg/mL (0.150 mEq/mL), 12,600 mg of sodium bicarbonate injection in 1,000 mL single-dose Viaflo container Injection: 12.6 mg/mL (0.150 mEq/mL), 12,600 mg of Sodium Bicarbonate Injection in 1,000 mL single-dose Viaflo container. (3)
Warnings/Precautions
- • Edema with Sodium Retention: Monitor patients who are sensitive to sodium intake (heart failure, hypertension, kidney disease, anuria, edema) for signs of fluid overload and adjust as appropriate. (5.1)
- • Electrolyte Imbalances: Therapy with sodium bicarbonate injection can result in metabolic alkalosis (associated with muscular twitchings, irritability and tetany) and hypernatremia. Monitor electrolytes periodically during administration and treat abnormalities appropriately. Dosing with sodium bicarbonate injection results in a large volume of administration in younger and lighter weight pediatric patients. Consider use of more concentrated sodium bicarbonate formulations in these pediatric populations. (5.2)
- • Extravasation: Prompt elevation of the area, warmth, and local injection of lidocaine or hyaluronidase are recommended to reduce the likelihood of tissue sloughing at the site. (5.3)
5.1 Edema with Sodium Retention
5.1 Edema with Sodium Retention Sodium bicarbonate injection can cause sodium retention and volume overload. Monitor patients who are sensitive to sodium intake (heart failure, hypertension, kidney disease, anuria, edema) for signs of fluid overload and adjust sources of sodium as appropriate.
5.2 Electrolyte Imbalances
5.2 Electrolyte Imbalances Sodium bicarbonate injection may cause electrolyte imbalances. Overly aggressive therapy with sodium bicarbonate injection can result in metabolic alkalosis (associated with muscular twitchings, irritability and tetany) and hypernatremia. Monitor electrolytes periodically during administration and treat abnormalities appropriately.
Dosing with sodium bicarbonate injection results in a large volume of administration in younger and lighter weight pediatric patients. Consider use of more concentrated sodium bicarbonate formulations in these pediatric populations [see Dosing and Administration (2)].
5.3 Extravasation
5.3 Extravasation Inadvertent extravasation of intravenously administered hypertonic solutions of sodium bicarbonate have been reported to cause chemical cellulitis because of their alkalinity, with tissue necrosis, ulceration or sloughing at the site of infiltration. Prompt elevation of the area, warmth, and local injection of lidocaine or hyaluronidase are recommended to reduce the likelihood of tissue sloughing at the site of intravenous solution extravasation.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Diuretics causing hypochloremic alkalosis | Avoid | Worsened alkalosis (label contraindication). | Do not use together. |
| Other sodium sources | Adjust or monitor | Additive sodium load (label 5.1). | Adjust total sodium intake. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Edema from sodium retention
- Electrolyte changes (hypernatremia, metabolic alkalosis, hypokalemia)
- Extravasation (chemical cellulitis)
Serious
- Fluid overload, heart failure
- Severe metabolic alkalosis with tetany
- Tissue necrosis after extravasation of hypertonic solution
- Hypernatremia and intracranial hemorrhage after rapid injection in infants
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in labeling: • Edema with Sodium Retention [see Warnings and Precautions (5.1)] • Electrolyte Imbalances [see Warnings and Precautions (5.2)] • Extravasation [see Warnings and Precautions (5.3)] Adverse reactions include edema with sodium retention, electrolyte imbalances and extravasation. (6) To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-877-725-2747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Monitoring parameters
- Blood gases or serum bicarbonate, sodium, potassium (hypokalemia as acidosis corrects), fluid status, blood pressure, edema. Extravasation site (hypertonic solutions). Kidney
- Bicarbonate or blood gases
- Sodium and potassium
- Fluid status and blood pressure
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available data from published literature over decades of use have not identified a drug associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Physiological replacement of sodium bicarbonate is not expected to lead to increased risk of adverse fetal or maternal outcomes.
Animal reproduction studies have not been conducted with sodium bicarbonate. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Mechanism of action
12.1 Mechanism of Action Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH.
US FDA labelPharmacokinetics
Key PK parameters
| Onset | Immediate (IV) |
|---|---|
| Metabolism (CYP, transporters) | Bicarbonate converted to carbon dioxide and water (lungs) |
| Renal excretion kidney | Under 1% of filtered bicarbonate in urine at normal function; excess excreted by the kidney |
| Dialyzability kidney | Crosses dialysis membranes (physiology) |
Bicarbonate anion is considered “labile” since at a proper concentration of hydrogen ion (H + ) it may be converted to carbonic acid (H 2 CO 3 ) and then to its volatile form, carbon dioxide (CO 2 ) excreted by the lung.
In a healthy adult with normal kidney function, practically all the glomerular filtered bicarbonate ion is reabsorbed; less than 1% is excreted in the urine.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Distribution Sodium bicarbonate in water dissociates to provide sodium (Na +) and bicarbonate (HCO 3 -) ions. Sodium (Na +) is the principal cation of the extracellular fluid. Bicarbonate (HCO 3 -) is a normal constituent of body fluids. Elimination Plasma bicarbonate concentration is regulated by the kidney through acidification of the urine when there is a deficit or by alkalinization of the urine when there is an excess.
Bicarbonate anion is considered “labile” since at a proper concentration of hydrogen ion (H +) it may be converted to carbonic acid (H 2 CO 3) and then to its volatile form, carbon dioxide (CO 2) excreted by the lung. In a healthy adult with normal kidney function, practically all the glomerular filtered bicarbonate ion is reabsorbed; less than 1% is excreted in the urine.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Sodium Bicarbonate 1 mEq/ mL, 20 mL Ampule | ₱68.23–₱144.75Reference ₱68.23 | per ampule | DPRI procurement range |
| Sodium Bicarbonate 1 meq/mL, 50 mL Ampule | ₱90.68–₱119.99Reference ₱90.68 | per ampule | DPRI procurement range |
| Sodium Bicarbonate 1 meq/mL, 50 mL Vial | ₱90.00–₱110.00Reference ₱90.00 | per vial | DPRI procurement range |
| Sodium Bicarbonate 650 mg Tablet | ₱0.99–₱5.25Reference ₱0.99 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Sodium Bicarbonate |
| PNF listing | Oral: 325 mg and 650 mg tablet |
| PNF listing | Inj.: 1 mEq/mL, 10 mL vial (pediatric), 20 mL, 50 mL and |
| PNF listing | Inj.: 100 mL ampul/vial (adult) (IV infusion) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. sodium bicarbonate · Baxter Healthcare Corporation [US FDA-approved label, version 1, August 14, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b50c858a-00c8-4cb2-ad73-8797f19e656d
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Baxter Healthcare Corporation. (2026). Sodium bicarbonate injection 12.6 mg/mL (isotonic) [Prescribing information; US FDA-approved label, NDA218524, set ID b50c858a-00c8-4cb2-ad73-8797f19e656d, version effective August 14, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b50c858a-00c8-4cb2-ad73-8797f19e656d
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .
